IJCM_118A: Pathway of healthcare for breast cancer: A mixed method study among women with breast cancer attending a tertiary healthcare institute in Bihar with the treatment, COVID-19 lockdown, informal providers/quacks)#9 out of 10 breast cancer patients had not come directly for definitive ...
Care pathway of women with interval breast cancer in 2016, based on medico-administrative dataChristine Le Bihan-Benjamin MDCamille BertrandFlorence MoliniéAgnès RogelJean-Baptiste MéricNorbert IfrahPhilippe-Jean Bousquet
Agency for Healthcare Research and Quality; 2024. AHRQ publication 23-05303-EF-2. 13. Trentham-Dietz A, Chapman CH, Jayasekera J, et al. Collaborative modeling to compare different breast cancer screening strategies: a decision analysis for the US Preventive Services Task Force. ...
Breast Cancer Research and Treatment is a comprehensive forum dedicated to all aspects of breast cancer research. The journal's focus spans across various ...
Inhibition of single-strand (SS) DNA break repair in tumour cells with homologous recombination deficiency33is synthetically lethal, and can cause cell death. Poly(ADP-ribose) polymerase-1 (PARP-1) is an integral enzyme in the repair pathway for SS DNA breaks; PARP-1 detects SS breaks and ...
Green represents patients at low residual risk following standard of care (eligible for future monitoring or treatment reduction trials). Purple/blue patients are those with treatment refractory tumors with candidate molecular drivers. Panel b: Overview of preclinical validation for pathway drivers. Given...
KNOWLEDGE AND CARE PATHWAY EVOLUTION FOR PATIENTS WITH METASTATIC BREAST CANCER BETWEEN 2015 AND 2021: RESULTS’ COMPARISON OF THE RÉALITÉS 1 AND 2 FRENCH SURVEYS Author links open overlay panelLefeuvre Claudia, Frenel Jean-Sebastien, Moley-Massol Isabelle, Guéroult-Accolas Laure, Debiais ...
(−) and CKMNF-116(+) (Fig.3i, j). Importantly, Her2 on the infiltrative foci was scored 3+ (positive) and Ki67 was expressed in 50% of the tumor cells, with a high impact on the patient’s correct treatment pathway. Another example of a Tru-cut biopsy from a 39-year-old ...
The majority of breast cancers express the estrogen receptor (ERα) and agents targeting this pathway represent the main treatment modality. Endocrine therapy has proven successful in the treatment of hormone-responsive breast cancer since its early adoption in the 1940s as an ablative therapy. Unfor...
IGF1R signaling results in activation of downstream effectors of the AKT-pathway and MAPK-pathway that function to control mRNA translation in breast cancer [4], [7]. However, the extent to which AIB1 participates in IGF-I stimulated mRNA translation in breast cancer is not known. The ...